SOURCE: Sunshine Biopharma Inc.

September 04, 2012 08:30 ET

Sunshine Biopharma Takes Delivery of Newly Manufactured Batch of Adva-27a and Proceeds to Conducting Biological Verification of the Compound's Anti-Cancer Activity

MONTREAL--(Marketwire - Sep 4, 2012) -  Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has taken delivery of an initial batch of Adva-27a from the Contract Manufacturing Organization (CMO) and has proceeded to conducting a series of requisite biological tests to ensure that the newly manufactured batch is identical to the original, not only in terms of chemical structure but also in terms of biological activity. Among the tests we will be performing are Topoisomerase II inhibition assays and cytotoxicity evaluations. The Topoisomerase II inhibition tests are already underway and the cytotoxicity evaluations will be initiated later this week. Adva-27a is Sunshine Biopharma's lead anti-cancer compound which has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).

"We are delighted to have advanced to this stage in our Adva-27a development program," said Dr. Steve N. Slilaty, Sunshine's President and CEO. "Biological testing is an important quality control procedure to ensure batch to batch identity in the manufacturing process," he added.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Contact Information